Bruker (NASDAQ:BRKR) Sets New 1-Year High Following Strong Earnings

Bruker Corporation (NASDAQ:BRKR) reached a new 52-week high during trading on Wednesday following a stronger than expected earnings report. The stock traded as high as $68.98 and last traded at $61.8820, with a volume of 1,051,428 shares traded. The stock had previously closed at $56.50.

The medical research company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.42 by $0.14. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%. The business had revenue of $874.00 million for the quarter, compared to analysts’ expectations of $865.16 million. During the same period in the prior year, the firm posted $0.45 EPS. The firm’s quarterly revenue was up 1.6% on a year-over-year basis.

Bruker Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, October 7th. Stockholders of record on Monday, September 21st were issued a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend was Monday, September 21st. Bruker’s dividend payout ratio is presently -28.57%.

Key Stories Impacting Bruker

Here are the key news stories impacting Bruker this week:

• Positive Sentiment: Bruker reported Q3 earnings per share of $0.56, beating the $0.42 consensus, and revenue of $874 million versus estimates of $865.16 million. Revenue increased 1.6% year over year. The earnings and sales beats are likely the main near-term positive catalysts. Bruker Q3 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Reports point to a return of U.S. academic demand in Q3, and Bruker is targeting double-digit EPS growth in FY2027. Improving demand and the growth target may bolster expectations for a stronger longer-term outlook. Bruker Sees U.S. Academic Demand Return
• Neutral Sentiment: FY2026 non-GAAP EPS guidance of $2.10–$2.15 brackets FactSet’s $2.12 estimate, leaving the outlook broadly in line with expectations. Bruker FY2026 EPS Guidance
• Negative Sentiment: FY2026 revenue guidance of $3.52–$3.56 billion has a midpoint below FactSet’s $3.56 billion estimate, suggesting limited near-term sales momentum. An earnings analysis also flags a steep goodwill charge, which tempers the headline results. Bruker FY2026 Revenue Guidance Bruker Q3 Margin and Goodwill Charge Analysis

Wall Street Analysts Forecast Growth

Several research firms recently commented on BRKR. UBS Group started coverage on Bruker in a report on Wednesday, September 9th. They issued a “neutral” rating and a $65.00 price objective for the company. Zacks Research cut shares of Bruker from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, September 2nd. TD Cowen raised their price target on shares of Bruker from $60.00 to $62.00 and gave the company a “hold” rating in a report on Tuesday, October 13th. Guggenheim lifted their price target on shares of Bruker from $70.00 to $72.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. Finally, Stifel Nicolaus set a $50.00 price objective on shares of Bruker in a report on Wednesday, August 5th. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Bruker has a consensus rating of “Moderate Buy” and a consensus target price of $59.43.

Insider Activity at Bruker

In other news, VP Mark Munch sold 2,000 shares of the company’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $52.87, for a total transaction of $105,740.00. Following the completion of the sale, the vice president owned 134,806 shares of the company’s stock, valued at $7,127,193.22. This represents a 1.46% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 27.20% of the stock is owned by insiders.

Institutional Trading of Bruker

Several large investors have recently added to or reduced their stakes in the business. Pallas Capital Advisors LLC bought a new position in Bruker in the second quarter worth approximately $570,746,000. Edmond DE Rothschild Holding S.A. purchased a new position in shares of Bruker during the 2nd quarter worth $169,899,000. Primecap Management Co. CA purchased a new position in shares of Bruker during the 2nd quarter worth $53,145,000. Bank of New York Mellon Corp bought a new stake in shares of Bruker during the 2nd quarter valued at $44,839,000. Finally, Old West Investment Management LLC bought a new stake in shares of Bruker during the 2nd quarter valued at $40,146,000. 79.52% of the stock is currently owned by institutional investors.

Bruker Price Performance

The company has a current ratio of 1.85, a quick ratio of 0.92 and a debt-to-equity ratio of 0.76. The stock has a market capitalization of $9.39 billion, a PE ratio of -88.02, a price-to-earnings-growth ratio of 1.70 and a beta of 1.26. The firm has a 50 day moving average price of $58.81 and a 200 day moving average price of $50.41.

About Bruker

Bruker Corporation develops and manufactures scientific instruments, analytical systems and related software used to study materials, molecules and biological processes. Its technologies support research, discovery and quality control in fields including life sciences, pharmaceutical development, chemical analysis, materials science, environmental testing and clinical research.

The company’s product portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, infrared and Raman spectroscopy instruments, X-ray analysis equipment, microscopy and nanoanalysis systems, and preclinical imaging technologies.